These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37496298)

  • 21. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
    Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
    Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
    Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
    Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
    Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
    Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
    Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
    Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
    Berger T; Shochat T; Aumann S; Nachmias B; Goldschmidt N; Horesh N; Harel R; Aviv A; Shmerts E; Abadi U; Shimony S; Raanani P; Gafter-Gvili A; Gurion R
    Ann Hematol; 2023 Aug; 102(8):2127-2136. PubMed ID: 37335322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
    Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
    Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P; Zhang H; Johnson R; Martín García-Sancho A; Provencio Pulla M; Trněný M; Yuen S; Tilly H; Kingsley E; Tumyan G; Assouline SE; Auer R; Ivanova E; Kim P; Huang S; Delarue R; Trotman J
    J Clin Oncol; 2023 Nov; 41(33):5107-5117. PubMed ID: 37506346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
    Younes A; Burke JM; Diefenbach C; Ferrari S; Khan C; Sharman JP; Tani M; Ujjani C; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Gilbertson M
    Blood Adv; 2022 Oct; 6(20):5659-5667. PubMed ID: 35359000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
    Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS; Ohna A; Krivasi T
    Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.